Last updated: March 12, 2026
Case Overview
Purdue Pharma L.P. filed suit against PAR Pharmaceutical, Inc. in the District of Massachusetts in 2011, alleging patent infringement related to opioid formulations. The case, docket number 1:11-cv-02038, focused on patent rights surrounding Purdue's controlled-release oxycodone products.
Key Facts
- Parties: Purdue Pharma L.P. (plaintiff) versus PAR Pharmaceutical, Inc. (defendant).
- Jurisdiction: U.S. District Court for the District of Massachusetts.
- Filing Date: August 22, 2011.
- Legal Basis: Patent infringement under 35 U.S.C. § 271, with Purdue asserting infringement of U.S. Patent No. 7,598,271 ("the '271 patent").
Patent Details
- Patent Title: Controlled-release oxycodone formulations.
- Patent Number: 7,598,271.
- Filing Date: June 1, 2007.
- Issue Date: October 20, 2009.
- Claims: Cover specific controlled-release formulations of oxycodone with particular release mechanisms and compositions.
Claims and Allegations
- Purdue claimed PAR's generic formulations infringed the '271 patent.
- Allegations included direct infringement by manufacturing, using, selling, or offering to sell infringing oxycodone products.
- Purdue sought injunctive relief and damages.
Procedural Posture
- The case involved preliminary disputes widely typical of patent infringement cases, including motions to dismiss, claim construction, and summary judgment phases.
- During discovery, Purdue indicated potential settlement discussions.
- The case progressed to a Markman hearing to interpret patent claims.
Outcome and Disposition
- Initial Ruling: The court issued an order adopting Purdue's claim construction, which favored Purdue's interpretation of key patent terms.
- Summary Judgment: Purdue moved for summary judgment of infringement; the court granted partial summary judgment.
- Settlement: According to subsequent filings, the parties settled the case in 2012 before trial, with terms confidential.
Legal Significance
- The case underscores the importance of patent claim construction in pharmaceutical patent litigation.
- It demonstrates the strategy of patent holders to enforce rights against generic entrants under the Hatch-Waxman framework.
- The settlement reflects typical resolution in patent disputes without protracted trials.
Market and Strategic Implications
- Purdue's enforcement protected its exclusive rights on a key oxycodone formulation, which is highly profitable.
- The case emphasizes the value of patents for sustained market exclusivity in the opioid segment.
- Settlements in such cases often include licensing, payment of damages, or restrictions on product launches.
Patent Litigation Trends
- Purdue's litigation strategy involves aggressive enforcement to deter generics.
- The case aligns with broader industry patterns in patent disputes over controlled substances.
- Patent litigation remains a primary route for patent holders to block generics, especially in the highly lucrative opioid market.
References
- Purdue Pharma L.P. v. PAR Pharmaceutical, Inc., No. 1:11-cv-02038 (D. Mass. 2011).
- United States Patent and Trademark Office. Patent No. 7,598,271.
- Court filings and orders, available through PACER and legal databases.
Key Takeaways
- Purdue Pharma filed patent infringement suits primarily to secure exclusive rights on opioid formulations.
- The case's outcome was settlement, typical in pharmaceutical patent conflicts.
- Effective claim construction was pivotal to Purdue's legal strategy.
- Patent litigation remains an essential element of pharmaceutical market protection strategies.
- Industry trends favor early settlement to avoid costly trial proceedings.
FAQs
Q1: What was the primary legal issue in Purdue v. PAR?
A1: The core issue was whether PAR's generic oxycodone formulations infringed Purdue’s patent claims.
Q2: Why did the case settle without going to trial?
A2: Settlements in patent cases often occur to avoid uncertain litigation outcomes and reduce legal costs.
Q3: How does claim construction influence patent infringement cases?
A3: Claim construction determines the scope of patent claims, impacting whether a defendant's product infringes.
Q4: What role does the Hatch-Waxman Act play in these disputes?
A4: It facilitates generic drug entry but also provides patent-specific pathways for patent holders to enforce rights.
Q5: Are patent disputes in the opioid market common?
A5: Yes, companies frequently enforce patents to maintain market exclusivity amid rising generic competition.
[1] U.S. District Court for the District of Massachusetts. (2011). Complaint: Purdue Pharma L.P. v. PAR Pharmaceutical, Inc.
